Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 2/20 | 0.50 |
| ▸ | PRKCA | P17252 | 2/20 | 0.50 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 2/20 | 0.47 |
| ▸ | PPARA | Q07869 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.47 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.47 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6976976 | 1.00 | FFAR1 (0.50) | FFAR1PRKCAPRKCDALOX5MAOB | |
| SCHEMBL8770928 | 0.86 | FFAR1 (0.51) | FFAR1PRKCAPRKCDALOX5MAOB | |
| SCHEMBL1915216 | 0.84 | SMN1; SMN2 (0.47) | POLBTDP1L3MBTL1MEN1MAPT | |
| SCHEMBL1915123 | 0.84 | SMN1; SMN2 (0.47) | POLBTDP1L3MBTL1MEN1MAPT | |
| SCHEMBL1915127 | 0.84 | SMN1; SMN2 (0.47) | POLBTDP1L3MBTL1MEN1MAPT | |
| SCHEMBL13118134 | 0.83 | FFAR1 (0.52) | FFAR1 | |
| SCHEMBL30771411 | 0.82 | SYK (0.53) | PRKCAPRKCDALOX5MAOBLTA4H | |
| SCHEMBL6741799 | 0.82 | PRKCA (0.46) | FFAR1PRKCAPRKCDALOX5MAOB | |
| SCHEMBL6741789 | 0.82 | PRKCA (0.46) | FFAR1PRKCAPRKCDALOX5MAOB | |
| SCHEMBL3523470 | 0.82 | FFAR1 (0.66) | FFAR1PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6689771-B2 | TREATMENT OF RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, PERIODONTITIS, GINGIVITIS, CORNEAL ULCERATION, SOLID TUMOR GROWTH | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-02-10 | — | — | US | disclosed |
| US-20030032803-A1 | Novel amide derivatives as inhibitors of matrix metalloproteinases, TNF-alpha, and aggrecanase | DUAN JINGWU (US) | 2003-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030032803-A1 | Novel amide derivatives as inhibitors of matrix metalloproteinases, TNF-alpha, and aggrecanase | TNF, MMP1, ADAMTS1 | FFAR1 2386/4885PRKCA 4160/4885PRKCD 4676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.